查找临床试验
已按「骨髓增生异常综合征」检索，对应国际通用词 myelodysplastic syndrome
共找到 287 项正在招募的试验（在欧美日韩等发达国家设有中心）
数据更新于 23:04，每 5 分钟自动同步Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
United States
年龄 7 Months – 21 Years
University of Wisconsin, Madison
A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias
United States
年龄 12 Years – 不限
Crossbow Therapeutics, Inc.
Luspatercept + Darbepoetin in MDS
United States
年龄 18 Years – 不限
Yale University
CHIP/CCUS Natural History Protocol
United States
年龄 18 Years – 99 Years
National Heart, Lung, and Blood Institute (NHLBI)
Prospective Evaluation of Diagnosis and Treatment of Patients With Autoimmune Cytopenias Including Autoimmune Hemolytic Anemia, Immune Thrombocytopenia, and Chronic Idiopathic/Autoimmune Neutropenia
Italy
年龄 18 Years – 不限
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Study for Epidemiology and Characterization of Myelodysplastic Syndromes (MDS) and Juvenile Myelomonocytic Leucemia (JMML) in Childhood
Germany
年龄 不限 – 17 Years
University Hospital Freiburg
Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations
United States、Belgium
年龄 18 Years – 不限
Blueprint Medicines Corporation
Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant
United States
年龄 18 Years – 75 Years
City of Hope Medical Center
CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
United States
年龄 18 Years – 不限
M.D. Anderson Cancer Center
A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts
United States
年龄 18 Years – 不限
M.D. Anderson Cancer Center
Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation
United States
年龄 18 Years – 不限
Dana-Farber Cancer Institute
A Study to Evaluate How Pozelimab + Cemdisiran Combination Therapy Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Whose Current Treatment is Not Working Efficiently
Brazil、Canada、Italy、Poland、South Korea 等 7 国
年龄 18 Years – 不限
Regeneron Pharmaceuticals